²ÝÁñÉçÇøÈë¿Ú

Email

jveerara@bcm.edu

Positions

Assistant Professor

Breast Center - Schiff-Osborne lab
²ÝÁñÉçÇøÈë¿Ú
Houston, TX US

Member

Dan L Duncan Comprehensive Cancer Center
²ÝÁñÉçÇøÈë¿Ú
Houston, Texas United States

Education

PhD from The University of Oklahoma Health Sciences Center

05/2012 - Oklahoma City, Oklahoma United States

Pathology

Professional Interests

• Cancer cell biology, Gene fusion, Preclinical tumor models, HER2-positive breast cancer, Precision Medicine, Treatment resistance, ERBB2 mutations, HER2-targeted therapy

Professional Statement

Through a correlative biomarker study using tumor specimens from chemotherapy-sparing neoadjuvant clinical trial, we recently demonstrated that there is a clinical subtype in breast cancer with high HER2 amplification and intact PI3K pathway that is especially sensitive to HER2-targeted therapy, without chemotherapy.
My current primary research interests are: i) delineate the mechanisms of resistance to potent HER2-targeted therapies, ii) unravel the genomic complexity of HER2-positive metastatic breast cancer, with a particular focus on brain metastasis, and iii) develop treatment strategies to effectively circumvent resistance and metastasis in HER2-positive breast cancer.

Websites

Selected Publications

• Veeraraghavan J, Tan Y, Cao X, Kim JA, Wang X, Chamness G.C, Maiti S.N, Laurence J.N. Cooper, Edwards D.P, Contreras A, Hilsenbeck S.G, Chang E.C, Schiff R and Wang X-S "." Nat Commun. 2014 Aug 7;5(1):1-12. Pubmed PMID:
• Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, et al., "." Clin Cancer Res. 2017 Jan 9;23(17):5123-5134. Pubmed PMID:
• Veeraraghavan J, De Angelis C, Reis-Filho JS, Prat A, Rimawi MF, Pascual T, Osborne CK, Schiff R. "." Breast. 2017 Aug;34(Suppl):S19-S26. Pubmed PMID:
• Goutsouliak K*, Veeraraghavan J*, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. *contributed equally "." Nat Rev Clin Oncol. 2020 Apr;17(4):233-250. Pubmed PMID:

Skills

Cancer cell and molecular biology